Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is -7.71% lower on its value in year-to-date trading and has touched a low of $16.57 and a high of $35.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ARWR stock was last observed hovering at around $17.11 in the last trading session, with the day’s gains setting it 0.24%.
Currently trading at $17.35, the stock is -10.44% and -10.89% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.43 million and changing 1.40% at the moment leaves the stock -21.97% off its SMA200. ARWR registered -51.91% loss for a year compared to 6-month loss of -27.19%.
The stock witnessed a -7.42% gain in the last 1 month and extending the period to 3 months gives it a -33.35%, and is -9.78% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.32% over the week and 5.62% over the month.
Arrowhead Pharmaceuticals Inc (ARWR) has around 609 employees, a market worth around $2.19B and $2.50M in sales. Profit margin for the company is -25588.56%. Distance from 52-week low is 4.71% and -51.54% from its 52-week high. The company has generated returns on investments over the last 12 months (-69.80%).
The EPS is expected to grow by 46.57% this year
The shares outstanding are 125.57M, and float is at 104.95M with Short Float at 8.99%.
The top institutional shareholder in the company is BLACKROCK INC. with over 15.68 million shares valued at $407.61 million. The investor’s holdings represent 12.7211 of the ARWR Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.21 million shares valued at $317.44 million to account for 9.9072 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 8.89 million shares representing 7.157 and valued at over $231.02 million, while FMR LLC holds 5.4849 of the shares totaling 6.81 million with a market value of $177.05 million.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Activity
A total of 0 insider transactions have happened at Arrowhead Pharmaceuticals Inc (ARWR) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Anzalone Christopher Richard, the company’s Chief Executive Officer. SEC filings show that Anzalone Christopher Richard sold 166,667 shares of the company’s common stock on Mar 03 ’25 at a price of $18.03 per share for a total of $3.01 million. Following the sale, the insider now owns 3.91 million shares.
Arrowhead Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 04 ’25 that Anzalone Christopher Richard (Chief Executive Officer) sold a total of 133,333 shares of the company’s common stock. The trade occurred on Mar 04 ’25 and was made at $17.02 per share for $2.27 million. Following the transaction, the insider now directly holds 3.77 million shares of the ARWR stock.
Still, SEC filings show that on Mar 04 ’25, Anzalone Christopher Richard (Officer) Proposed Sale 133,333 shares at an average price of $17.02 for $2.27 million. The insider now directly holds shares of Arrowhead Pharmaceuticals Inc (ARWR).
Arrowhead Pharmaceuticals Inc (ARWR): Who are the competitors?
One of the company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading -23.80% down over the past 12 months.Johnson & Johnson (JNJ) lies in the list of competitors of the Arrowhead Pharmaceuticals Inc and is 3.63% higher over the same period from ARWRLigand Pharmaceuticals Inc. (LGND) is 58.73% up on the 1-year trading charts.
